2850367-41-6
Chemical Structure
Amlenetug
Synonym(s): Lu-AF82422
- CAS No.: 2850367-41-6
- Molecular Weight:(144.09 kDa)
SMILES: [Amlenetug]
Biological Activity: Amlenetug (Lu-AF82422) is a blood-brain barrier-penetrant monoclonal antibody targeting the C-terminal ILEDMP epitope of α-synuclein and recognizes multiple forms of α-synuclein. Amlenetug reduces plasma and cerebrospinal fluid α-synuclein levels by inhibiting its seeding, neuronal uptake, aggregation, and spreading, and by clearing aggregates from brain homogenates of multiple system atrophy, Parkinson's disease, and dementia with Lewy bodies. Amlenetug can be used in research on multiple system atrophy, Parkinson's disease, and synucleinopathies[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Amlenetug | 99.85% | Amlenetug (Lu-AF82422) is a blood-brain barrier-penetrant monoclonal antibody targeting the C-terminal ILEDMP epitope of α-synuclein and recognizes multiple forms of α-synuclein. Amlenetug reduces plasma and cerebrospinal fluid α-synuclein levels by inhibiting its seeding, neuronal uptake, aggregation, and spreading, and by clearing aggregates from brain homogenates of multiple system atrophy, Parkinson's disease, and dementia with Lewy bodies. Amlenetug can be used in research on multiple system atrophy, Parkinson's disease, and synucleinopathies. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kallunki P, et al. Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies. NPJ Parkinson's disease. 2025 May 22;11(1):132. [Content Brief]
- [2]. Kjærsgaard L, et al. Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial. The Lancet Neurology, 2026; 25, 560-570.
- [3]. Liu Y, et al. Comparative assessment of binding and functional differences of clinical antibodies targeting α-synuclein in cellular models of Parkinson's disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2025 Aug;189:118262. [Content Brief]
- [4]. Fjord-Larsen L, et al. Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. mAbs. 2021;13(1):1994690. [Content Brief]
